These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 330766)

  • 1. Radiographic measurement of topical corticosteroid-induced atrophy.
    Snyder DS; Greenberg RA
    J Invest Dermatol; 1977 Sep; 69(3):279-81. PubMed ID: 330766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurement of skin thickness: a comparison of two in vivo techniques with a conventional histometric method.
    Dykes PJ; Marks R
    J Invest Dermatol; 1977 Sep; 69(3):275-8. PubMed ID: 894062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of potential skin atrophy following topical application of weak corticosteroids.
    Black MM; Platt NE; Mugglestone CJ
    Curr Med Res Opin; 1981; 7(7):463-70. PubMed ID: 7261664
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study.
    Queille-Roussel C; Paul C; Duteil L; Lefebvre MC; Rapatz G; Zagula M; Ortonne JP
    Br J Dermatol; 2001 Mar; 144(3):507-13. PubMed ID: 11260007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative atrophogenicity potential of medium and highly potent topical glucocorticoids in cream and ointment according to ultrasound analysis.
    Kerscher MJ; Korting HC
    Skin Pharmacol; 1992; 5(2):77-80. PubMed ID: 1637562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the atrophogenic potential of different glucocorticoids using optical coherence tomography, 20-MHz ultrasound and profilometry; a double-blind, placebo-controlled trial.
    Cossmann M; Welzel J
    Br J Dermatol; 2006 Oct; 155(4):700-6. PubMed ID: 16965418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Methods for the assessment of skin atrophogenicity of topical corticosteroids.
    Marks R
    Dermatologica; 1976; 152 Suppl 1():117-26. PubMed ID: 133834
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved risk-benefit ratio for topical triamcinolone acetonide in Transfersome in comparison with equipotent cream and ointment: a randomized controlled trial.
    Fesq H; Lehmann J; Kontny A; Erdmann I; Theiling K; Rother M; Ring J; Cevc G; Abeck D
    Br J Dermatol; 2003 Sep; 149(3):611-9. PubMed ID: 14510997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Domoprednate (Stermonid), a topical D-homocorticosteroid, skin atrophy and telangiectasia. A double-blind, randomized comparison with hydrocortisone butyrate, betamethasone valerate, clobetasole propionate and placebo.
    Serup J; Holm P
    Dermatologica; 1985; 170(4):189-94. PubMed ID: 3888708
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of bufexamac (NFN) cream in skin diseases. A double-blind multicentre trial.
    Christiansen JV; Gadborg E; Kleiter I; Ludvigsen K; Meier CH; Norholm A; Reiter H; Reymann F; Raaschou-Nielsen W; Sondergaard M; Unna P; Wehnert R
    Dermatologica; 1977; 154(3):177-84. PubMed ID: 140084
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent application of tretinoin (retinoic acid) partially protects against corticosteroid-induced epidermal atrophy.
    McMichael AJ; Griffiths CE; Talwar HS; Finkel LJ; Rafal ES; Hamilton TA; Voorhees JJ
    Br J Dermatol; 1996 Jul; 135(1):60-4. PubMed ID: 8776360
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical experiences with hydrocortisone 17-butyrate.
    Yasuda T
    Dermatologica; 1976; 152 Suppl 1():221-9. PubMed ID: 782956
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The kinetics of skin thinning induced by topical fluticasone propionate 0.05% cream in volunteer subjects.
    Dykes PJ; Marks R; Hill S; Mills C; Eastwood R
    Clin Exp Dermatol; 1996 May; 21(3):180-4. PubMed ID: 8914356
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparison of triamcinolone acetonide MDI with a built-in tube extender and beclomethasone dipropionate MDI in adult asthmatics.
    Berkowitz R; Rachelefsky G; Harris AG; Chen R
    Chest; 1998 Sep; 114(3):757-65. PubMed ID: 9743163
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroid-induced dermal atrophy in the rat.
    Young JM; Yoxall BE; Wagner BM
    J Invest Dermatol; 1977 Nov; 69(5):458-62. PubMed ID: 908845
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ultrasonic assessment of cutaneous atrophy caused by intradermal corticosteroids.
    Gomez EC; Berman B; Miller DL
    J Dermatol Surg Oncol; 1982 Dec; 8(12):1071-4. PubMed ID: 7153406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Reducing the dosage by new technology].
    Steinhorst M
    Hautarzt; 2001 Jan; 52(1):p following 90 (91). PubMed ID: 11220248
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of skin atrophy and vasoconstriction due to mometasone furoate, methylprednisolone and hydrocortisone.
    Hoffmann K; Auer T; Stücker M; Hoffmann A; Altmeyer P
    J Eur Acad Dermatol Venereol; 1998 Mar; 10(2):137-42. PubMed ID: 9553910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Measurement of dermal atrophy induced by topical steroids using a radiographic technique.
    James MP; Black MM; Sparkes CG
    Br J Dermatol; 1977 Mar; 96(3):303-5. PubMed ID: 322693
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of atrophogenicity of popularly prescribed topical corticosteroids.
    Dykes PJ; Marks R; Blakemore CB
    Br J Clin Pract; 1978 Dec; 32(12):345-8. PubMed ID: 737113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.